ARTICLE | Discovery & Translation
Three tensions in early-stage translation: BioCentury Grand Rounds
Across disciplines, researchers are navigating trade-offs in advancing translation that boil down to scope versus focus
September 27, 2024 11:43 PM UTC
When it comes to maximizing the therapeutic impact of early-stage R&D, you can’t have it all — at least not without new paradigms.
Companies and academics must either pick which parameters are most important to them, or innovate new paths that thread the needle between often opposed factors. At heart, it boils down to a question of scope versus focus. ...